Zura Bio (ZURA) Stock Price, News & Analysis

Company Overview

Zura Bio, Inc. is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases. By combining advanced protein engineering with established conjugation chemistry, Zura Bio seeks to generate a pipeline of drug candidates that offer superior stability, optimized pharmacokinetics and enhanced safety profiles. Preclinical studies to date have demonstrated the potential of these conjugates to achieve targeted delivery while minimizing systemic exposure.

In addition to its internal pipeline, Zura Bio collaborates with academic institutions and industry partners to explore novel applications of its bioconjugation technology. These partnerships are intended to accelerate the translation of platform innovations into clinical-stage programs and to broaden the range of payloads that can be delivered using site-specific conjugation methods. The company’s approach is designed to be modular, allowing collaborators to integrate payloads of interest onto clinically proven protein backbones.

Based in Berkeley, California, Zura Bio serves global markets by engaging with biotechnology and pharmaceutical companies seeking to enhance the performance of their protein-based therapeutics and diagnostic tools. With a leadership team experienced in protein engineering and drug development, the company is positioned to advance its conjugation platform toward first-in-human studies and to establish strategic alliances that further validate the broad utility of its technology.

Key Stats

• Today's Range: $5.03 to $5.43
• 50-Day Range: $3.40 to $5.90
• 52-Week Range: $1.08 to $7.44
• Volume: 926,095 shs
• Average Volume: 1.46 million shs
• Market Capitalization: $508.56 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.75
• Consensus Rating: Moderate Buy

Zura Bio Stock Analysis - MarketRank™

Zura Bio scored higher than 55% of companies evaluated by MarketBeat, and ranked 363rd out of 848 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Zura Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 1 strong buy rating, 3 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Zura Bio has a consensus price target of $10.75, representing about 100.6% upside from its current price of $5.36.

Amount of Analyst Coverage

Zura Bio has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Zura Bio are expected to grow in the coming year, from ($0.76) to ($0.65) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Zura Bio is -4.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Zura Bio is -4.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Zura Bio has a P/B Ratio of 3.88. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

7.06% of the float of Zura Bio has been sold short.

Short Interest Ratio / Days to Cover

Zura Bio has a short interest ratio ("days to cover") of 5.39.

Change versus previous month

Short interest in Zura Bio has recently decreased by 5.57%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Zura Bio does not currently pay a dividend.

Dividend Growth

Zura Bio does not have a long track record of dividend growth.

News and Social Media

• Score: 1.3 / 5
• News Sentiment: N/A

News Sentiment

Zura Bio has a news sentiment score of 0.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Zura Bio this week, compared to 2 articles on an average week.

Search Interest

Only 2 people have searched for ZURA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Zura Bio insiders have not sold or bought any company stock.

Percentage Held by Insiders

12.37% of the stock of Zura Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

61.14% of the stock of Zura Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/07/2026
• Today: 7/06/2026
• Next Earnings (Estimated): 8/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ZURA
• CIK: 1855644
• Web: N/A
• Phone: 858-247-0520
• Fax: N/A
• Employees: 3
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Zura Bio: $10.75
• High Price Target: $15.00
• Low Price Target: $2.00
• Potential Upside/Downside: +100.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.09)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$99.35 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -55.74%
• Return on Assets: -48.07%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 19.33
• Quick Ratio: 19.33

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.38 per share
• Price / Book: 3.88

Miscellaneous

• Outstanding Shares: 94,880,000
• Free Float: 83,144,000
• Market Cap: $508.56 million
• Optionable: Optionable
• Beta: -0.03